Crescent Biopharma (CBIO) Free Cash Flow (2013 - 2026)
Crescent Biopharma (CBIO) reported Free Cash Flow of -$9.0 million for Q1 2026, up 16.63% year-over-year from -$7.8 million in Q1 2025, and up 65.19% quarter-over-quarter from -$26.0 million in Q4 2025.
Crescent Biopharma (CBIO) Free Cash Flow (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 14 years of Free Cash Flow data on file, last reported at -$9.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$9.0 million, up 16.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$69.7 million (down 167.94% YoY), and the FY2025 annual result was -$71.5 million, down 129.87% from the prior year.
- Free Cash Flow climbed to -$9.0 million in Q1 2026 per CBIO's latest filing, from -$26.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$6.3 million in Q4 2024 and troughed at -$26.0 million in Q4 2025.
- A 5-year average of -$11.7 million and a median of -$9.8 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow surged 57.07% in 2023, then tumbled 314.63% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$7.9 million in 2022, then rose by 3.74% to -$7.6 million in 2023, then grew by 17.68% to -$6.3 million in 2024, then tumbled by 314.63% to -$26.0 million in 2025, then jumped by 65.19% to -$9.0 million in 2026.
- Business Quant data shows CBIO's Free Cash Flow at -$9.0 million in Q1 2026, -$26.0 million in Q4 2025, and -$18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | -9.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.05 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Dec 31, 2025 | -25.99 Mn |
| Dec 31, 2025 | -25.99 Mn |
| Sep 30, 2025 | -18.08 Mn |
| Sep 30, 2025 | -18.08 Mn |
| Jun 30, 2025 | -16.59 Mn |
| Jun 30, 2025 | -16.59 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Mar 31, 2024 | -10.52 Mn |
| Mar 31, 2024 | -10.52 Mn |
| Dec 31, 2023 | -7.62 Mn |
| Dec 31, 2023 | -7.62 Mn |
| Sep 30, 2023 | -8.69 Mn |
| Sep 30, 2023 | -8.69 Mn |